Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527088 | 0.86 | DHODH (0.49) | ALDH1A1MAPTHSD17B10GPR119HPGD | |
| SCHEMBL19689700 | 0.86 | GPR119 (0.47) | ALDH1A1MAPTHSD17B10SMN1; SMN2GPR119 | |
| SCHEMBL380505 | 0.86 | DHODH (0.49) | ALDH1A1MAPTHSD17B10GPR119HPGD | |
| SCHEMBL28675181 | 0.85 | GPR119 (0.46) | ALDH1A1MAPTHSD17B10SMN1; SMN2GPR119 | |
| SCHEMBL21724876 | 0.85 | GPR119 (0.46) | ALDH1A1MAPTHSD17B10SMN1; SMN2GPR119 | |
| SCHEMBL21042103 | 0.84 | GPR119 (0.45) | ALDH1A1MAPTHSD17B10GPR119HPGD | |
| SCHEMBL846218 | 0.84 | HDAC1 (0.53) | ALDH1A1MAPTSMN1; SMN2GPR119HPGD | |
| SCHEMBL30681278 | 0.84 | GPR119 (0.45) | ALDH1A1MAPTHSD17B10GPR119HPGD | |
| SCHEMBL13691905 | 0.82 | DHODH (0.53) | ALDH1A1MAPTSMN1; SMN2GPR119TSHR | |
| SCHEMBL1058537 | 0.82 | NR1H2 (0.62) | MAPTSMN1; SMN2GPR119DHODHRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641881-B | 1-tetrahydropyranyl carbonyl-2, 3-dihydro-1H-indole compounds for use in the treatment of cancer | 伊莱利利公司 | 2022-01-07 | — | — | CN | disclosed |
| US-10759786-B2 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer | ELI LILLY AND COMPANY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3468965-B1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | LILLY CO ELI (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20190161477-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER | ELI LILLY AND COMPANY | 2019-05-30 | — | — | US | disclosed |
| EP-3468965-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | Eli Lilly and Company (US) | 2019-04-17 | — | — | EP | disclosed |
| US-9872853-B2 | 2,3-dihydro-1H-indole compounds | ELI LILLY AND COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170354641-A1 | 2,3-DIHYDRO-1H-INDOLE COMPOUNDS | ELI LILLY AND COMPANY | 2017-12-14 | — | — | US | disclosed |
| WO-2017213919-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | ELI LILLY AND COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161477-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER | MCL1, IDO1, GLI1 | ALDH1A1 227/4885MAPT 3345/4885HSD17B10 2167/4885 |
| US-10759786-B2 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer | MCL1, FOXM1, IDO1 | ALDH1A1 234/4885MAPT 3015/4885HSD17B10 3546/4885 |
| US-20170354641-A1 | 2,3-DIHYDRO-1H-INDOLE COMPOUNDS | MCL1, IDO1, IDO2 | ALDH1A1 148/4885MAPT 3006/4885HSD17B10 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.